Diagnosis, management, and treatment of hepatitis C: An update
By M. Ghany, D. Strader, David L. Thomas, L. Seeff. Hepatology, 2009
3,377 citations recorded by the source corpus.
This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/f6b3bb8c2ffe87e4796ded6ec41aa05a3fa889c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity (2014, background): “Persistent infection with HCV is a major cause of human liver damage in over 3% of the world’s population, and consequently, these patients are at risk of developing advanced liver diseases and liver cancer [4].”
- Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. (2013, neutral): “(1 00 [7 2– 10 0] ) 6/ 10 (6 0 [2 6– 88 ]) 9/ 9”
- Sofosbuvir for previously untreated chronic hepatitis C infection. (2013, neutral): “Patients who completed treatment 25/320 (8) 71/242 (29) 37/188 (20)”
- KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, methodology): “This represents the current standard of care for HCV infection.(342,355) Treatment regimens for HCV-associated GN and the doses of individual agents will vary with the severity of the kidney disease.”
- Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014, neutral): “Lymphocyte count 350 to <500/mm3 0 1 (1) 5 (2)”